Enhabit (NYSE:EHAB) Issues FY 2024 Earnings Guidance

Enhabit (NYSE:EHAB) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.190-0.290 for the period, compared to the consensus EPS estimate of 0.270. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.1 billion.

Enhabit Trading Down 0.4 %

Shares of Enhabit stock traded down $0.03 during trading hours on Friday, hitting $7.89. The company’s stock had a trading volume of 566,776 shares, compared to its average volume of 315,521. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market capitalization of $396.71 million, a PE ratio of -3.40 and a beta of 1.84. The stock has a 50 day moving average of $7.59 and a 200 day moving average of $8.57.

Enhabit (NYSE:EHAB) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. The business had revenue of $260.60 million for the quarter, compared to analyst estimates of $265.99 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.61%. During the same period last year, the business posted $0.04 earnings per share. Analysts predict that Enhabit will post 0.26 earnings per share for the current year.

Insider Buying and Selling at Enhabit

In other Enhabit news, Director Jeffrey Bolton bought 5,000 shares of Enhabit stock in a transaction that occurred on Thursday, August 22nd. The stock was acquired at an average price of $8.01 per share, for a total transaction of $40,050.00. Following the completion of the acquisition, the director now owns 78,877 shares of the company’s stock, valued at $631,804.77. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.90% of the company’s stock.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.